BACK ISSUES of PULLAN'S PIECES
March 2025- Pullan's Pieces #212
Linda: Big pharma deals in 2025?
Linda: Big pharma unprecedented targets in CV, CNS, metabolic
Kristine: ADC Trends
Trevor: Soft landing optimism
February 2025 - Pullan's Pieces #211
Linda: Rare disease landscape
Linda: RNA binding proteins
Kristine: China Biotech
Trevor: The money-spending business
January 2025 - Pullan's Pieces #210
Linda: Amgen- an evolving company
Kristine: Anti-PD1xVEGF opportunity
Trevor: Seed to series A
November 2024 - Pullan's Pieces #209
Linda: Big Pharma Immunology in Preclinical and Discovery
Linda: Deals are down!
Kristine: Obesity therapeutics
Trevor: XBI better than S&P
October 2024 - Pullan's Pieces #208
Linda: The Pfizer Activist Challenge
Linda: How competitive is partnering your drug?
Kristine: Investing in Private Biotechs
Trevor: Betting on everything
September 2024 - Pullan's Pieces #207
Linda: Where are the drugs?
Linda: China snapshot
Kristine: Novel targets in Alzheimer's and Parkinson's
Trevor: Rate cut and XBI falls
August 2024- Pullan's Pieces #206
Linda: Early-stage fund-raising remains hard
Linda: Licensing and M&A uneven
Kristine: The IRA and Orphan Drugs
Trevor: More optimism?
July 2024- Pullan's Pieces #205
Linda: Where are the sales?
Linda: Your BATNA
Kristine: Pharma Option and License Deals
Trevor: Head and Shoulders?
June 2024- Pullan's Pieces #204
Linda: MASH- the old NASH is newly exciting
Linda: Gilead - a snapshot
Kristine: M&A: What does Pharma want?
Trevor: Market Sentiment: On more solid footing..
May 2024- Pullan's Pieces #203
Linda: IPOs of 2024
Linda: Market cap per employee and other stats by territory
Kristine: Option Deals in Biotech
Trevor: Market Sentiment: Marking Time?